Melanoma and Immunotherapy

Alexander M.M. Eggermont, Dirk Schadendorf

Research output: Contribution to journalReview articlepeer-review

41 Citations (Scopus)


About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.

Original languageEnglish
Pages (from-to)547-564
Number of pages18
JournalHematology/Oncology Clinics of North America
Issue number3
Publication statusPublished - Jun 2009
Externally publishedYes


  • Antibodies
  • Cytokines
  • Immunotherapy
  • Melanoma
  • Review
  • Vaccines


Dive into the research topics of 'Melanoma and Immunotherapy'. Together they form a unique fingerprint.

Cite this